Gilead Sciences, Inc. $GILD Shares Bought by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in Gilead Sciences by 2.2% during the first quarter, now holding approximately 750,516 shares valued at about $84 million.
• Gilead Sciences reported earnings of $2.01 per share for the last quarter, exceeding analysts' expectations, and anticipates a FY 2025 guidance of $7.950-$8.250 EPS.
• The company declared a quarterly dividend of $0.79 per share, representing a 2.7% dividend yield, to be paid on September 29th.

Woodline Partners LP lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 750,516 shares of the biopharmaceutical company's stock after buying an additional 15,823 shares during the quarter. Gilead Sciences comprises 0.5% of Woodline Partners LP's portfolio, making the stock its 27th biggest holding. Woodline Partners LP owned 0.06% of Gilead Sciences worth $84,095,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in GILD. Brighton Jones LLC raised its stake in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $215,000. Focus Partners Wealth increased its stake in Gilead Sciences by 14.7% in the 4th quarter. Focus Partners Wealth now owns 117,736 shares of the biopharmaceutical company's stock worth $10,875,000 after acquiring an additional 15,048 shares during the last quarter. Graham Capital Management L.P. bought a new stake in Gilead Sciences in the 4th quarter worth approximately $1,744,000. Finally, Jacobs Levy Equity Management Inc. increased its stake in Gilead Sciences by 27.6% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 648,386 shares of the biopharmaceutical company's stock worth $59,891,000 after acquiring an additional 140,095 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 2.8%

GILD traded down $3.31 during trading hours on Friday, reaching $114.55. 6,466,956 shares of the company's stock traded hands, compared to its average volume of 5,830,447. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a 50-day moving average price of $114.04 and a 200 day moving average price of $110.09. The firm has a market capitalization of $142.13 billion, a PE ratio of 22.82, a PEG ratio of 0.80 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $81.57 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.